Navigation Links
Cornerstone Pharmaceuticals Announces The Journal of Molecular Medicine's Publication of Research Showing Selective Inhibition of Cancer Cell Energy Metabolism With Its Novel Lipoate Derivative Compounds
Date:7/25/2011

CRANBURY, N.J., July 25, 2011 /PRNewswire/ -- Cornerstone Pharmaceuticals, Inc., (www.cornerstonepharma.com), a leader in the growing field of cancer metabolism-based therapeutics, today announced the publication of a paper in The Journal of Molecular Medicine (http://tinyurl.com/3ugohzd) describing the selective inhibition of cancer cell energy metabolism by its novel lipoate derivative compounds.  Specifically, the publication illuminates the mechanism by which CPI-613, a lipoic acid analog, selectively attacks the regulatory aspects of tumor cell mitochondrial metabolism, activating both apoptotic (programmed cell death) and non-apoptotic (necrosis-like) cell death pathways.  This research was conducted in collaboration between scientists at Stony Brook University and Cornerstone Pharmaceuticals. The paper "Non-redox-active lipoate derivatives disrupt cancer cell mitochondrial metabolism and are potent anti-cancer agents in vivo" is available today in the advanced online publication of The Journal of Molecular Medicine. The full author's version of the paper is available here: http://tinyurl.com/3gvx5oa

"The highly reconfigured metabolism of cancer cells has recently gained wide attention as a possible source of novel drug targets," said Dr. Zuzana Zachar, Ph.D., the lead author of the paper who is Director of Research at Cornerstone and a Research Assistant Professor at Stony Brook University School of Medicine.  

"CPI-613 attacks cancer cell metabolism in a powerful new way, yielding very strong anti-cancer effects in pre-clinical human tumor models," added Dr. Paul Bingham, Ph.D., co-author, and Vice President of Research at Cornerstone and Associate Professor at Stony Brook University School of Medicine.

CPI-613 is the lead drug candidate from Cornerstone's Altered Energy Metabolism Directed (AEMD) platform.  Dr. Zachar's paper states that CPI-613 induces cancer-specific regulatory hyper-phosphorylation of the E1 subunits of the centrally important TCA enzyme complex, pyruvate dehydrogenase (PDH), resulting in the inhibition of PDH function.  These and related cancer-specific effects of the drug lead to catastrophic disruption of tumor mitochondrial metabolism. Tumor cells are thereby starved of energy and biosynthetic intermediates, culminating in cell death.  

The paper also reports that CPI-613 is a potent inhibitor of human tumor growth in pre-clinical animal models, producing apparent tumor clearance in some animals.  CPI-613 strongly inhibits tumor growth in a non-small cell human lung cancer and a human pancreatic cancer pre-clinical mouse tumor model.  In the pancreatic model, treated animals were further examined for long term survival after completion of a brief treatment regimen and a substantial fraction showed no tumor regrowth.

Robert Shorr, CEO, added "This research demonstrates that our active analogs of lipoic acid can act as potent anti-cancer agents that are highly selective in animal models by disrupting the activity of at least one key bioenergetic enzyme.  In view of the novel mechanism of action of these drugs and their potency in pre-clinical models, it is of great interest to assess their efficacy in human clinical trials and to be able to predict which patients will be most likely to benefit."

"Alterations in cancer cell metabolism are distinctive hallmarks of cancer and represent a new frontier in the development of novel and selective classes of chemotherapeutic interventions for use in the treatment of cancer.  Candidates for application of this new approach are so far, very few and lipoate analogs such as CPI-613 represent a promising new addition," said Dr. Bob Weinberg, a member of Cornerstone's scientific advisory board and a founder and member of the Whitehead Institute at MIT.

Cornerstone's proprietary Altered Energy Metabolism Directed (AEMD) drug platform disrupts biochemical alterations in the conversion of glucose to energy that occur in many types of cancer cells. These essential "bioenergetic" differences are linked to pathways that control, among other things, cancer cell growth and development, as well as various forms of cell death, including apoptosis and necrosis. The platform is designed to produce drugs, such as the company's lead drug CPI-613, that disrupt energy-production pathways whose organization or regulation are altered specifically in cancer cells. CPI- 613 is currently being evaluated in several ongoing Phase I/II trials.

About Cornerstone Pharmaceuticals

Cornerstone Pharmaceuticals, Inc. is a privately held company that is committed to changing the way cancer is treated through the discovery and development of innovative therapies capitalizing on the unique metabolic processes of cancer cells. The company's founding members, management and scientific advisory team include pre-eminent scientists focused on cancer cell metabolism, cancer research and drug development. The company's unique approach to targeting cancer metabolism has led to the discovery of first-in-class drugs with the potential to transform the way cancer is treated.  www.CornerstonePharma.com

This release contains forward-looking statements. These statements relate to future events or each company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

Media Contact: Meghan Weber
Liza Sullivan & Associates
(917) 399-8713
news@cornerstonepharma.com


'/>"/>
SOURCE Cornerstone Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Wake Forest Baptist Medical Center and Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial of CPI-613 in Acute Myeloid Leukemia
2. Cornerstone Pharmaceuticals Announces Positive Results of Emulsiphan Safety Study
3. Cornerstone Therapeutics to Host Fourth Quarter and Full Year 2010 Conference Call
4. Cornerstone Therapeutics to Host Third Quarter 2010 Conference Call
5. Cornerstone Therapeutics Announces Development of Generic for Tussionex®
6. Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept
7. Cornerstone Therapeutics Announces Collaboration with The Cough Company
8. Cornerstone Therapeutics to Host Second Quarter 2010 Conference Call
9. Cornerstone Therapeutics Announces Management Change
10. Cornerstone Therapeutics To Present at Deutsche Banks 35th Annual Healthcare Conference
11. Cornerstone Therapeutics to Host First Quarter 2010 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 8, 2016   GS1 US will hold ... them through GS1 Standards implementation to address the requirements ... Device Identification (UDI) rule. Scott Brown ... Gibson , senior director industry development, medical devices, GS1 ... GS1 US --> Scott Brown ...
(Date:2/8/2016)... Pa. , Feb. 8, 2016   ... November Research Group (NRG),s pharmacovigilance technology services ... system-related consulting services and an Oracle Argus Specialized ... services to Life Sciences companies. ... and expands HighPoint,s life sciences capabilities and provides ...
(Date:2/8/2016)... , Switzerland and PALO ALTO, Calif. ... in biological and chemical manufacturing, and Kodiak Sciences Inc., ... the treatment of retinal disease, announced today agreements for ... agreement, Lonza will manufacture material at multiple sites, including ... --> --> Retinal diseases, ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... ... is famous for gift giving with flowers, chocolates and other tokens of affection meant to ... more than 5.6 million Americans suffering with Alzheimer’s, those store bought gifts - no ... lives they’ve led and the people they’ve touched. , That’s why Give ...
(Date:2/8/2016)... ... 2016 , ... Steve Helwig & Associates Insurance & Financial, serving the families ... teamed up with Citizens Opposed to Domestic Abuse in support of its efforts to ... those victimized by the fear of violence in their own homes, donations may now ...
(Date:2/8/2016)... ... February 08, 2016 , ... Remember the old saying “rub some ... to Perry A~, author of “Calcium Bentonite Clay” the health benefits of integrating clay ... and detoxifying the body. , A former motivational speaker, Perry A~ has since dedicated ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... this important news! AHCC and the Home Health and Hospice ICD-10 Transition Workgroup ... for official ICD coding guidance and clarifications, to address concerns over the use ...
(Date:2/8/2016)... ... February 08, 2016 , ... According to research by the ... dental technicians to be certified or obtain continuing education. To increase patient awareness ... In Your Mouth?” campaign to inform dentists and patients about the possible lack ...
Breaking Medicine News(10 mins):